Transgene (Euronext Paris:TNG) announced a licensing agreement with closely-held CDMO, ProBioGen, for the AGE1.CR.pIX suspension cell line.
The companies seek to add value by partnering to combine ProBioGen’s specific production technology with the manufacturing capabilities of Transgene’s individualized cancer vaccine program and its myvac platform.
Dr. Alessandro Riva, CEO of Transgene, stated, “We are delighted to embark on this collaborative journey with ProBioGen. The AGE1.CR.pIX suspension cell line represents a significant addition to further expand the manufacturing processes while we work towards providing patients with tailored patient-specific therapies against cancer on a larger scale.”
“We are thrilled to partner with Transgene in advancing the frontier of personalized cancer vaccines,” commented Dr. Volker Sandig, CSO of ProBioGen. “Our collaboration holds immense potential to impact the personalized vaccine space and to offer new treatments and hope to cancer patients.”
